NUVB Stock Overview
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Nuvation Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.62 |
| 52 Week High | US$4.16 |
| 52 Week Low | US$0.95 |
| Beta | 1.37 |
| 1 Month Change | -9.03% |
| 3 Month Change | 52.33% |
| 1 Year Change | 64.78% |
| 3 Year Change | -77.39% |
| 5 Year Change | n/a |
| Change since IPO | -72.99% |
Recent News & Updates
Recent updates
Nuvation Bio: Strong Buy Off The Acquisition Of A Late-Stage Lung Cancer Candidate
Mar 31Nuvation: Cash Is King, Science Is An Afterthought
Oct 03We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Sep 14
Seth Klarman's Baupost adds Herbalife, Altice USA, exits Dropbox, Enhabit
Feb 14We're Hopeful That Nuvation Bio (NYSE:NUVB) Will Use Its Cash Wisely
Feb 10We Think Nuvation Bio (NYSE:NUVB) Can Afford To Drive Business Growth
Nov 09Nuvation Bio GAAP EPS of -$0.12 beats by $0.02
Nov 03Shareholder Returns
| NUVB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 1.6% | 0.08% | 1.2% |
| 1Y | 64.8% | 13.2% | 24.9% |
Price Volatility
| NUVB volatility | |
|---|---|
| NUVB Average Weekly Movement | 17.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NUVB's share price has been volatile over the past 3 months.
Volatility Over Time: NUVB's weekly volatility has increased from 11% to 18% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 51 | David Hung | www.nuvationbio.com |
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company’s lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
Nuvation Bio Inc. Fundamentals Summary
| NUVB fundamental statistics | |
|---|---|
| Market cap | US$698.61m |
| Earnings (TTM) | -US$75.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-9.1x
P/E RatioIs NUVB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUVB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$75.80m |
| Earnings | -US$75.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NUVB perform over the long term?
See historical performance and comparison